Pilot Project to Examine the Effects of Exercise on Nocturnal Lipolysis in Men and Women

June 27, 2019 updated by: University of Colorado, Denver
The goal of this proof of concept/feasibility study is to use rigorous methodology to explore links between daytime energy status and nocturnal fat metabolism in healthy adults.

Study Overview

Status

Completed

Conditions

Detailed Description

This primary goal of this pilot project is to obtain preliminary data demonstrating the feasibility of measuring lipolysis and fat oxidation during sleep in adult human subjects using microdialysis, stable isotope labeling techniques, and whole-room indirect calorimetry. The results of this study will be used in grant applications to perform definitive studies using these methods. The long term goal of this line of research is to explore the mechanisms responsible for sex based differences in the effectiveness of physical activity as an approach to weight loss. Previous longitudinal data have shown that in normal weight and obese individuals, for any given increase in physical activity, there is a significantly greater loss of fat mass in men relative to women [Westerterp, 1997]. These data need to be reconciled, however, with the wealth of data demonstrating that during exercise, women release and oxidize fat more readily than men [Horton, 2009; Horton 1998, Moro 2007]. This phenomenon seems counterintuitive, given that men have less body fat than women and are able to lose more body fat than women when beginning a weight loss program [Bjorntorp, 2007]. Recent data suggests a mechanism to explain this paradox. Specifically, in obese subjects, 24-hour fat oxidation increased following a daytime bout of exercise, and this increase occurred in men only and was driven by a significant increase in fat oxidation not during the day but rather during sleep the night following exercise [Bergouignan, 2014]. Since the predominant source of fuel during sleep is free fatty acids (FFA) released from adipose tissue (i.e., lipolysis), it may be that enhanced sleeping lipolysis is a key factor in how exercise stimulates fat oxidation and thus greater fat loss in males vs. females over time.

The primary objective of the proposed study is to demonstrate the feasibility of measuring nocturnal whole-body and regional lipolysis by using stable isotope techniques and microdialysis of subcutaneous abdominal adipose tissue respectively with the long term goal of determining the effects of acute exercise during the daytime on rates of lipolysis at night in men and women. A secondary objective of this study is to determine if nocturnal regional lipolysis measured by microdialysis of subcutaneous abdominal adipose tissue and whole body lipolysis measured by a stable glycerol isotope infusion are related to dietary and whole body fat oxidation measured by stable isotope labelled fatty acid and whole-room calorimetry, respectively. Finally, the study aims to determine if sleep quality parameters measured by EEG and wrist actigraphy correlate with measures of nocturnal fat oxidation and lipolysis (regional and whole body)

Study Type

Observational

Enrollment (Actual)

15

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Colorado
      • Aurora, Colorado, United States, 80045
        • University of Colorado Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Healthy Adults

Description

Inclusion Criteria:

  • Males and Females, 20-35 years of age
  • Sedentary (planned exercise < 3 d/week, < 30 min/session)
  • Lifetime maximum BMI of 30 kg/m2
  • Weight stable by self-report for at least 2 mo before the study (<5% weight change)
  • Habitual sleeping pattern of >7 hours not to exceed 9.25 hours of sleep per night
  • Zero to low-moderate caffeine intake (not to exceed 500 mg/d)
  • Alcohol use fewer than two standard drinks per day per week for males and one or less drinks per day per week for females.

Exclusion Criteria:

  • Current smoker
  • Use of any medication that could affect lipid metabolism, insulin signaling, or sleep
  • Pregnant women will not be enrolled in the study
  • Current or chronic medical/psychiatric conditions
  • Shift work or dwelling below Denver altitude (1,600 m) a year prior to testing
  • Travel across more than one time zone 3 wk before study
  • Abnormal eating patterns identified by interview and eating questionnaire
  • Screening positive for illicit drugs
  • Chronic health conditions such as diabetes,
  • Hyper or hypothyroidism
  • Sleep apnea (Apnea-Hypopnea Index >5)
  • Renal or liver disease, anemia, or cancer
  • Regularly go to sleep after midnight
  • One or more of the following out-of-range values measured on a fasting blood sample:

    • glucose > 110 mg/dl,
    • thyroid stimulating hormone <0.5 or >5.0 uU/ml,
    • hemoglobin < 14.5 g/dl men, <12.3 g/dl women,
    • alanine amino transferase > 47 U/l,
    • aspartate aminotransferase > 47 U/l,
    • alkaline phosphatase <39 or >117 U/l, or
    • creatinine >1.1 mg/dl.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Lipolysis
Time Frame: Overnight (2200h-0700h)
Measured using stable isotope tracers and microdialysis
Overnight (2200h-0700h)
Change in Substrate Oxidation
Time Frame: 24 hours
Measured using whole-room calorimetry
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Sleep Quality
Time Frame: Overnight (2200h-0700h)
Measured using wrist actigraphy
Overnight (2200h-0700h)
Change in Lipolytic Hormones
Time Frame: Overnight (2200h-0700h)
Frequent blood sampling to measure growth hormone, cortisol, catecholamines, and other lipolytic hormones
Overnight (2200h-0700h)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Daniel Bessesen, MD, University of Colorado, Denver

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2015

Primary Completion (Actual)

September 1, 2017

Study Completion (Actual)

September 1, 2017

Study Registration Dates

First Submitted

March 30, 2015

First Submitted That Met QC Criteria

April 2, 2015

First Posted (Estimate)

April 3, 2015

Study Record Updates

Last Update Posted (Actual)

July 1, 2019

Last Update Submitted That Met QC Criteria

June 27, 2019

Last Verified

June 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 13-0359

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

3
Subscribe